Profile data is unavailable for this security.
About the company
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
- Revenue in USD (TTM)76.81m
- Net income in USD-518.67m
- Incorporated2000
- Employees376.00
- LocationMadrigal Pharmaceuticals Inc200 Barr Harbor Dr Ste 400WEST CONSHOHOCKEN 19428-2978United StatesUSA
- Phone+1 (404) 380-9263
- Fax+1 (302) 655-5049
- Websitehttps://www.madrigalpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biohaven Ltd | 0.00 | -746.61m | 5.26bn | 239.00 | -- | 12.87 | -- | -- | -9.15 | -9.15 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -137.07 | -- | -176.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
| Crinetics Pharmaceuticals Inc | 1.39m | -258.54m | 5.42bn | 290.00 | -- | 5.79 | -- | 3,914.07 | -3.77 | -3.77 | 0.0201 | 10.47 | 0.0023 | -- | 0.4157 | 4,775.86 | -41.16 | -42.53 | -44.29 | -45.36 | -- | -- | -18,257.91 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
| Arcellx Inc | 155.82m | -40.42m | 5.54bn | 130.00 | -- | 11.52 | -- | 35.55 | -0.7196 | -0.7196 | 2.98 | 8.95 | 0.226 | -- | -- | 1,198,600.00 | -5.86 | -38.82 | -7.56 | -45.41 | -- | -- | -25.94 | -339.38 | -- | -- | 0.022 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
| Krystal Biotech Inc | 241.52m | 52.37m | 5.74bn | 229.00 | 112.95 | 6.48 | 96.63 | 23.77 | 1.77 | 1.77 | 8.21 | 30.80 | 0.2725 | 1.51 | 4.53 | 1,054,664.00 | 5.91 | -11.50 | 6.33 | -12.01 | 92.55 | -- | 21.68 | -492.85 | 7.76 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
| Ionis Pharmaceuticals Inc | 803.07m | -358.81m | 6.19bn | 927.00 | -- | 9.34 | -- | 7.71 | -2.45 | -2.45 | 5.50 | 4.20 | 0.267 | 0.3864 | 10.02 | 866,306.40 | -11.93 | -6.30 | -13.52 | -7.44 | 98.70 | 98.75 | -44.68 | -21.23 | 8.82 | -- | 0.6587 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
| Nuvalent Inc | 0.00 | -173.59m | 6.23bn | 115.00 | -- | 9.69 | -- | -- | -2.78 | -2.78 | 0.00 | 9.84 | 0.00 | -- | -- | 0.00 | -31.08 | -- | -32.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
| Blueprint Medicines Corp | 434.41m | -128.05m | 6.41bn | 638.00 | -- | 20.43 | -- | 14.74 | -2.11 | -2.11 | 6.92 | 4.93 | 0.3769 | 0.8954 | 8.11 | 663,227.50 | -11.11 | -29.92 | -13.84 | -34.06 | 97.01 | -- | -29.48 | -116.65 | 3.27 | -10.80 | 0.5525 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
| Cytokinetics, Inc. | 3.22m | -576.40m | 6.82bn | 423.00 | -- | -- | -- | 2,119.26 | -5.39 | -5.39 | 0.0301 | -0.118 | 0.003 | -- | 2.35 | 7,609.93 | -52.96 | -43.14 | -57.95 | -47.22 | -- | -- | -17,906.24 | -540.47 | -- | -14.27 | 1.02 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
| Legend Biotech Corp (ADR) | 455.99m | -285.01m | 7.38bn | 2.20k | -- | 6.33 | -- | 16.18 | -1.57 | -1.57 | 2.51 | 6.33 | 0.2446 | 10.63 | 32.42 | 253,328.30 | -15.29 | -37.71 | -17.63 | -47.19 | 60.28 | -- | -62.50 | -286.51 | 4.78 | -- | 0.2263 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
| Viking Therapeutics Inc | 0.00 | -99.15m | 7.63bn | 33.00 | -- | 8.37 | -- | -- | -0.937 | -0.937 | 0.00 | 8.18 | 0.00 | -- | -- | 0.00 | -15.02 | -21.91 | -15.47 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
| Madrigal Pharmaceuticals Inc | 76.81m | -518.67m | 7.65bn | 376.00 | -- | 9.84 | -- | 99.58 | -25.07 | -25.07 | 3.71 | 35.64 | 0.1172 | -- | -- | 204,289.90 | -79.11 | -62.09 | -100.35 | -74.81 | 96.37 | -- | -675.24 | -- | 5.93 | -- | 0.1309 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
| Exact Sciences Corp | 2.69bn | -214.04m | 9.53bn | 6.50k | -- | 2.97 | 5,226.40 | 3.54 | -1.17 | -1.17 | 14.70 | 17.35 | 0.4089 | 5.40 | 11.60 | 414,204.30 | -3.25 | -9.71 | -3.58 | -10.60 | 72.96 | 74.10 | -7.95 | -28.21 | 1.93 | -- | 0.4459 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| Revolution Medicines Inc | 742.00k | -567.06m | 10.17bn | 490.00 | -- | 6.47 | -- | 13,702.40 | -3.59 | -3.59 | 0.0047 | 9.34 | 0.0005 | -- | 4.80 | 1,962.96 | -41.28 | -29.76 | -44.46 | -32.59 | -- | -- | -76,423.31 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Exelixis Inc | 2.08bn | 466.92m | 10.35bn | 1.31k | 23.10 | 4.55 | 20.93 | 4.97 | 1.57 | 1.57 | 6.92 | 7.96 | 0.7012 | 3.39 | 8.04 | 1,589,006.00 | 15.73 | 8.86 | 18.08 | 9.91 | 96.25 | 96.30 | 22.43 | 15.43 | 3.88 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
Data as of Nov 08 2024. Currency figures normalised to Madrigal Pharmaceuticals Inc's reporting currency: US Dollar USD
71.66%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 30 Jun 2024 | 2.48m | 11.41% |
| Avoro Capital Advisor LLCas of 30 Jun 2024 | 2.06m | 9.47% |
| Baker Bros. Advisors LPas of 30 Jun 2024 | 1.97m | 9.09% |
| RTW Investments LPas of 30 Jun 2024 | 1.92m | 8.82% |
| Paulson & Co., Inc.as of 30 Jun 2024 | 1.85m | 8.52% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.76m | 8.10% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 1.27m | 5.83% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Jun 2024 | 841.27k | 3.88% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 744.71k | 3.43% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 673.98k | 3.10% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
